Metadherin, a novel oncogenic gene in malignant pleural mesothelioma

Authors

• L Zhang
• CD Hoang

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer, accounting for 3,000 deaths in the US annually. The incidence will peak at 15-20 years in the western hemisphere. The majority of patients receive chemotherapy as treatment, but inherent chemoresistance of MPM limits efficacy. The molecular mechanism(s) of MPM resistance to chemotherapy remain poorly defined. To identify candidate genes of MPM, a meta-analysis, using a novel algorithm combining effect size and P values, on MPM from 111 samples of four public data sets was performed. 32 up- and 36 down-regulated genes were identified in MPM with p

Scientific Focus Area: Cancer Biology

This page was last updated on Friday, March 26, 2021